Linked Life Data

10824135

Source:http://linkedlifedata.com/resource/pubmed/id/10824135

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2000-7-28
pubmed:abstractText
Butamben (butyl p-aminobenzoate) has been formulated to provide long-acting treatment for chronic pain. The suspension, which contains poly(ethylene glycol) and polysorbate 80, was found to yellow under ambient conditions if not adequately protected from oxygen. The impurity responsible for the color was isolated and identified on the basis of nuclear magnetic resonance spectroscopy and mass spectrometry. The compound is an oxalamidine, which is formally the condensation product of oxalic acid with four equivalents of butamben, and may be formed by the reaction of butamben with an oxidation product of poly(ethylene glycol).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0022-3549
pubmed:author
pubmed:copyrightInfo
Copyright 2000 Wiley-Liss, Inc. and the American Pharmaceutical Association J Pharm Sci 89:766-770, 2000.
pubmed:issnType
Print
pubmed:volume
89
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
766-70
pubmed:dateRevised
2000-12-18
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Identification of a yellow impurity in aged samples of aqueous butamben suspension: evidence for the oxidative degradation of poly(ethylene glycol).
pubmed:affiliation
Hospital Products Division, Abbott Laboratories, Department 97D, Building AP4, 100 Abbott Park Road, Abbott Park, Illinois 60064-6076, USA. eric.ginsburg@abbott.com
pubmed:publicationType
Journal Article